GlassScriptPhysician profile
Audrey E Arzamendi
NPI 1508159567
$12,723.81
in general payments reported to CMS, 2019-2025
45 companies · $200 in 2025
The $200 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,082 · 2020: $624 · 2021: $849 · 2022: $2,130 · 2023: $2,475 · 2024: $1,364 · 2025: $200.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,864 · Consulting Fee: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,864.46 |
| Consulting Fee | $175.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $4,117.69 | 2019-2024 | Korlym |
| Novo Nordisk INC | $1,316.43 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $893.95 | 2019-2025 | Prolia, Evenity, Prolia |
| Lilly USA, LLC | $877.70 | 2019-2024 | Jardiance, Mounjaro, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $682.11 | 2022-2024 | |
| Radius Health, INC. | $636.31 | 2019-2024 | Tymlos |
| Mannkind Corporation | $625.84 | 2019-2024 | Afrezza |
| Abbvie INC. | $323.62 | 2019-2023 | Synthroid |
| Sanofi-Aventis U.S. LLC | $319.91 | 2019-2024 | |
| Medtronic, INC. | $284.22 | 2021-2024 | Venaseal, Minimed 780g |
| Boehringer Ingelheim Pharmaceuticals, INC. | $269.31 | 2020-2024 | Jardiance |
| Antares Pharma, INC. | $257.22 | 2019-2024 | Xyosted, Nocdurna, Tlando |
| Abbott Laboratories | $206.38 | 2019-2023 | Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $163.09 | 2019-2020 | |
| Xeris Pharmaceuticals, INC. | $135.27 | 2020-2023 | Gvoke Hypopen |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Recordati_rare_diseases_inc. | $134.37 | 2022-2024 | Signifor Lar, Isturisa |
| Dexcom, INC. | $125.65 | 2019-2023 | Dexcom G6 Transmitter |
| Halozyme INC | $123.93 | 2023 | |
| Merck Sharp & Dohme LLC | $97.51 | 2019-2021 | |
| Amarin Pharma, INC. | $87.25 | 2020 | |
| Ibsa Pharma INC. | $82.03 | 2019-2020 | |
| Horizon Therapeutics Plc | $79.47 | 2020-2022 | |
| Tandem Diabetes Care, INC. | $78.46 | 2022-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Verity Pharmaceuticals INC. | $78.23 | 2024 | Tlando |
| Vivus LLC | $70.77 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $59.44 | 2019-2022 | |
| Kyowa Kirin, INC. | $53.45 | 2023 | Crysvita |
| Bigfoot Biomedical INC | $51.70 | 2021-2022 | |
| Almatica Pharma LLC | $50.31 | 2024-2025 | Teriparatide |
| Zealand Pharma US, INC. | $45.20 | 2021 | |
| Insulet Corporation | $40.76 | 2019 | |
| Beta Bionics, INC. | $39.75 | 2024 | Ilet Bionic Pancreas |
| Cequr Corporation | $38.63 | 2022-2023 | Cequr Simplicity |
| Currax Pharmaceuticals LLC | $32.87 | 2023 | Nexletol, Nexlizet, Contrave |
| Alexion Pharmaceuticals, INC. | $32.82 | 2021 | |
| Nevro Corp. | $29.31 | 2022 | |
| Ascendis Pharma Endocrinology INC | $26.90 | 2023 | |
| Amryt Pharma Holdings LTD | $24.18 | 2023 | Mycapssa |
| Eusa Pharma (US) LLC | $20.99 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $20.89 | 2021 | |
| Ascensia Diabetes Care US INC. | $20.73 | 2024 | |
| Medtronic Minimed, INC. | $19.80 | 2019 | |
| Rgh Enterprises LLC | $19.41 | 2023 | |
| Pfizer INC. | $19.02 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $10.93 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Audrey Arzamendi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.